Aromatase inhibitor
Pills that stop the body making oestrogen (after the menopause, when it comes from fat and muscle rather than the ovaries), starving hormone receptor-positive breast cancer. Taken for five to ten years after surgery, they halve recurrence.
Letrozole, anastrozole and exemestane block the aromatase enzyme; in premenopausal women they only work with ovarian function suppression (GnRH agonist or oophorectomy, SOFT/TEXT). They modestly beat tamoxifen in postmenopausal adjuvant therapy (ATAC, BIG 1-98) and are the partner drug for CDK4/6 inhibitors in metastatic disease. Side effects are joint pain, bone loss (needing bisphosphonates), vaginal dryness and cardiovascular effects, and adherence over 5-10 years is a real problem. Resistance often comes through ESR1 mutations, which favour switching to a SERD.
Pages like this
not linked directly; found by shared links- PersonWendy Parulekar
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialSOFT & TEXT
Shares Letrozole (and other aromatase inhibitors), Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TechnologySoy foods and breast cancer
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonBernard Fisher
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PairingCDK4/6 inhibitor + endocrine therapy
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- Key paperIBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialPALOMA-2
Shares Letrozole (and other aromatase inhibitors), HR-positive / HER2-negative breast cancer.
- TechnologyDietitian-led weight-loss programmes in HR-positive breast cancer
Shares Letrozole (and other aromatase inhibitors), Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.